

Bonnie K Harrington

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8453868/publications.pdf>

Version: 2024-02-01

33
papers

2,175
citations

430442

18
h-index

414034

32
g-index

33
all docs

33
docs citations

33
times ranked

3488
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal hematopoiesis of indeterminate potential in the companion dog. <i>Leukemia</i> , 2022, 36, 1401-1403.	3.3	2
2	DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo. <i>Small</i> , 2022, 18, .	5.2	40
3	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 17.	6.9	31
4	Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. <i>Journal of Hematology and Oncology</i> , 2021, 14, 36.	6.9	9
5	Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 101.	6.9	8
6	Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 6338.	5.8	3
7	Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 139.	6.9	39
8	1/4-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6260-6273.	3.2	17
9	Modulation of immune checkpoint molecule expression in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2498-2507.	0.6	21
10	Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 242-255.	2.5	38
11	Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. <i>Blood Advances</i> , 2019, 3, 447-460.	2.5	42
12	BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. <i>Cancer Discovery</i> , 2018, 8, 458-477.	7.7	101
13	The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. <i>Cancer Discovery</i> , 2018, 8, 1300-1315.	7.7	115
14	Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. <i>International Immunology</i> , 2018, 30, 375-383.	1.8	21
15	PI3K p110 β inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. <i>Journal of Clinical Investigation</i> , 2018, 129, 122-136.	3.9	42
16	CD37 Expression in Acute Myeloid Leukemia Provides New Target for Directed Therapy. <i>Blood</i> , 2018, 132, 4056-4056.	0.6	1
17	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2831-2841.	3.2	123
18	NF- κ B p50 (nfb1) contributes to pathogenesis in the 1/4-TCL1 mouse model of chronic lymphocytic leukemia. <i>Blood</i> , 2017, 130, 376-379.	0.6	12

#	ARTICLE	IF	CITATIONS
19	BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia. <i>Blood Advances</i> , 2017, 1, 2147-2160.	2.5	5
20	Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. <i>PLoS ONE</i> , 2016, 11, e0159607.	1.1	49
21	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 323-332.	13.9	785
22	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. <i>Cancer Research</i> , 2016, 76, 2125-2136.	0.4	150
23	BRAFV600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia. <i>Blood</i> , 2016, 128, 1206-1206.	0.6	3
24	The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3941-3941.	0.6	3
25	ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity. <i>Blood</i> , 2015, 126, 2908-2908.	0.6	15
26	The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2920-2920.	0.6	7
27	A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vitro Potency in B-Cell Malignancies. <i>Blood</i> , 2015, 126, 318-318.	0.6	0
28	Histiocytic Sarcoma and Bilateral Facial Vein Thrombosis in a Siberian Hamster (<i>Phodopus sungorus</i>). <i>Comparative Medicine</i> , 2015, 65, 127-32.	0.4	5
29	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4867-4876.	3.9	173
30	Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2014, 28, 1158-1163.	3.3	55
31	Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis. <i>BMC Cancer</i> , 2014, 14, 84.	1.1	36
32	Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). <i>Blood</i> , 2014, 123, 1207-1213.	0.6	176
33	Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. <i>Blood</i> , 2013, 122, 3308-3316.	0.6	48